Although azanucleoside DNA-hypomethylating agents (HMAs) are routinely used for the treatment of myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), very few outcome predictors have been established. Expression of the b-like globin gene locus is tightly regulated by DNA methylation, is HMA-sensitive in vitro, and fetal haemoglobin (HbF) expression is under study as a potential biomarker for response of MDS patients to azacitidine. We determined HbF expression in 16 MDS and 36 AML patients receiving decitabine (DAC). Pre-treatment HbF was already elevated (>1Á0% of total haemoglobin) in 7/16 and 12/36 patients, and HbF was induced by DAC in 81%/54% of MDS/AML patients, respectively. Elevated pre-treatment HbF was associated with longer median overall survival (OS): 26Á6 vs. 8Á6 months for MDS (hazard ratio [HR] 8Á56, 95% confidence interval [CI] 1Á74-42Á49, P = 0Á008, with similarly longer progression-free and AML-free survival), and 10Á0 vs. 2Á9 months OS for AML (HR 3Á01, 95% CI 1Á26-7Á22, P = 0Á014). In a multivariate analysis, the prognostic value of HbF was retained. Time-dependent Cox models revealed that the prognostic value of treatment-induced HbF induction was inferior to that of pre-treatment HbF. In conclusion, we provide first evidence for in vivo HbF induction by DAC in MDS/AML, and demonstrate prognostic value of elevated pre-treatment HbF, warranting prospective, randomized studies.
DNA hypomethylating agents (HMAs) have become accepted as the first-line treatment for older patients with myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML); however, despite an overall survival (OS) benefit with azacitidine in higher-risk MDS (Fenaux et al, 2009 ) and with decitabine (DAC) or Aza in AML (Kantarjian et al, 2012; Dombret et al, 2015) , 40-60% of patients do not achieve an objective response to treatment. Even in responsive patients, the development of resistance is frequent, limiting the longterm outcome of this non-curative treatment (when administered without subsequent allogeneic blood stem cell transplantation). In recent years, substantial efforts have been undertaken to identify outcome predictors to HMAs. These include clinical parameters (age, performance status, cytogenetics, blast percentage, early platelet increases during treatment, time from MDS diagnosis to treatment start) as well as genetic and epigenetic parameters, such as mutational status of frequently altered genes and the methylation status of informative candidate genes such as CDKN2B (previously termed p15/INK4b; reviewed by Treppendahl et al, 2014) .
Fetal haemoglobin (HbF) is composed of two a-and two c-globin chains. During embryogenesis, the majority of haemoglobin is composed of HbF, and during globin switching (beginning at birth), c-chain transcription is silenced by DNA promoter methylation, with the b-globin gene (HBB) becoming demethylated and activated (van der Ploeg & Flavell, 1980) . After that, the development-specific control of gene transcription at the b-globin-like gene locus constitutes one of the preeminent paradigms for tissue-and differentiation-specific epigenetic gene regulation (reviewed by Saunthararajah et al, 2014). Thus it is not surprising that HbF constitutes an attractive candidate in the search for a novel, rational outcome predictor following epigenetic therapy: it is known to be inducible -both in vitro and in vivo -by HMAs and other epigenetically active agents in MDS and AML patients (Gore et al, 2006; Tan et al, 2014) , in b-thalassaemia (Ley et al, 1982) , sickle-cell anaemia (Koshy et al, 2000; Saunthararajah et al, 2008) and solid tumours, such as renal cell carcinoma (Gollob et al, 2006) and non-small cell lung cancer (Chu et al, 2013) . However, there has been a paucity of larger studies addressing the prognostic value of pre-treatment HbF in MDS/AML. In an earlier study (Reinhardt et al, 1998) , HbF was variably elevated in 16 of 26 MDS patients, and this appeared to be associated with longer OS in this heterogeneously treated cohort. In contrast, in children with juvenile myelomonocytic leukaemia (JMML), elevated HbF is known to herald a dismal prognosis (Niemeyer et al, 1997) , and in 100 children with acute leukaemias, it was also predictive of worse outcome (Rautonen & Siimes, 1990) .
In the present study, we prospectively conducted the first determination of serial HbF measurements in 51 MDS and AML patients treated with DAC. Patients were enrolled on two clinical trials, the 06011 European Organization for Research and Treatment of Cancer-German MDS Study Group (EORTC-GMDSSG) phase III trial of higher-risk MDS, and the 00331 phase II trial of older, non-fit AML. We interrogated this parameter with regard to its distribution at baseline, its kinetics over time with treatment, and, as a potential clinical application, its prognostic value with this treatment.
Patients and methods

MDS patients, treatment and response evaluation
The EORTC/GMDSSG phase III trial 06011 enrolled MDS patients aged ≥60 years who were ineligible for induction chemotherapy and had 11-30% bone marrow blasts and/or poor-risk cytogenetics according to the International Prognostic Scoring System (IPSS). Patients randomised to the DAC treatment arm received the drug as previously described (L€ ubbert et al, 2011) , i.e. nine 4-h infusions of 15 mg/m 2 given over 72 h, repeated every 6 weeks for a minimum of four courses. Responses were assessed according to the International Working Group criteria (Cheson et al, 2000 (Cheson et al, , 2003 .
The primary endpoint, OS, was defined as time from random assignment until death of any cause or last follow-up (censored observation). The secondary endpoints were progression-free survival (PFS), defined as time from random assignment to progression, relapse after attainment of complete remission (CR) or partial response (PR), or death, whichever occurred first, and AML-free survival (AMLFS; defined as time from random assignment to AML transformation or death of any cause, whichever occurred first). The study was approved by the institutional review board of the University of Freiburg Medical Centre, and written informed consent was given according to the Declaration of Helsinki.
AML patients, treatment and response evaluation
The 00331 phase II trial enrolled patients aged 61 years or older with previously untreated de novo or secondary AML following MDS (by French-American-British classification [Bennett et al, 1976] , i.e. with >30% bone marrow blasts) who were scored as ineligible for induction chemotherapy. DAC was administered as previously described (L€ ubbert et al, 2012) , i.e. with nine 3-h infusions of 15 mg/m 2 given over 72 h, repeated every 6 weeks for four courses. Patients with a CR, PR or an anti-leukaemic effect (ALE) at evaluation of course 4 were eligible for maintenance treatment with DAC at 20 mg/m 2 (given intravenously for 1 h on three consecutive days, repeated every 6-8 weeks). CR was defined as a nonblastic marrow aspirate (blast cells <5%), platelet count >100 9 10 9 /l, white blood cell (WBC) count >1Á5 9 10 9 /l, and no extramedullary leukaemia. PR was defined as a cellular marrow aspirate with 5-25% blasts, with platelet count >100 9 10 9 /l, WBC count >1Á5 9 10 9 /l, and no clinical or imaging evidence of leukaemia; or a cellular marrow aspirate with <5% blasts, platelet count <100 9 10 9 /l and WBC count <1Á5 9 10 9 /l. An ALE was defined as >25% reduction of bone marrow blasts relative to the initial blast percentage but not enough to fulfil PR criteria. Progressive disease (PD) was defined as a >25% relative increase in blasts in peripheral blood or bone marrow compared to before start of treatment. Stable disease (SD) was defined by the absence of a CR, PR or ALE, and no PD. Death of any cause occurring within 6 weeks after initiation of DAC treatment was defined as early death. OS was defined as time from treatment start until death from any cause or last follow-up (censored observation). The study was approved by the institutional review board of the University of Freiburg Medical Centre, and written informed consent was given according to the Declaration of Helsinki.
Haemoglobin quantification
HbF levels were measured (Biss e & Wieland, 1988) by high performance liquid chromatography (HPLC) before treatment and sequentially, i.e. after the end of each treatment course (every 6 weeks). After preparation of protein solution, chromatography was performed on a chromatography system (L-1100 series; Hewlett Packard, Santa Clara, CA, USA) using a reversed phase column (RP 300-5; Macherey Nagel, D€ uren, Germany). Protein chains were eluted from the column using a denaturing acetonitrile (ACN) buffer system with a continuous ACN gradient at room temperature. Flow rate was 1Á0 ml/min. Haemoglobin protein chains were detected by ultraviolet-visible (UV-VIS) spectrometry at 220 nm. Patients were grouped by normal (HbF ≤ 1%) or elevated HbF levels (HbF > 1%), in accordance with reference values for the University of Freiburg Medical Centre Central Laboratory.
Statistical methods
Statistical analyses were performed with SAS 9.2 (SAS Institute Inc., Cary, NC, USA), and SPSS Statistics 22 (IBM, Armonk, NY, USA). Possible associations between categorical factors were investigated with Fisher's exact test, exact significance level, two-sided. Patients' OS and, for MDS patients, PFS and AMLFS times, were calculated as described above. Patients in whom the event of interest was not observed were considered as censored observations. Overall survival, PFS and AMLFS rates and median survival times were estimated with the Kaplan-Meier method and compared using the logrank test. Furthermore, uniand multivariate Cox proportional hazards models were applied in order to analyse the impact of possible prognostic factors. Results are presented as hazard ratios (HRs) with accompanying two-sided 95% confidence interval (CI). Cox regression models were also applied to incorporate HbF measurements (≤1 vs. >1) obtained during study treatment as a time-dependent covariate, thus assessing whether the prognostic value of this parameter changes over time. The additional gain of HbF as a prognostic factor was evaluated by entering HbF in a multivariate model, where age ≥75 years and lactate dehydrogenase (LDH) ≥300 U/l were included as known relevant prognostic factors.
Results
Haemoglobin F is variably expressed in MDS/AML patients and induced following treatment with Decitabine
Serial determinations of HbF protein (by HPLC) were conducted on peripheral blood samples of 16 of the 19 MDS/ AML patients treated with DAC on the 06011 randomised phase III trial at the Freiburg study centre (no HbF measurements are available for the first 3 patients randomised to the DAC arm at this centre). Patient characteristics are displayed in Table I . Measurements were taken at randomisation and then before initiation of each subsequent treatment course, i.e. approximately every 6 weeks.
For these 16 patients, the median HbF level prior to treatment was 0Á4% of total haemoglobin (range 0Á1-3Á9%). In seven of these 16 patients, HbF levels at baseline were already elevated (1Á7%, range 1Á1-3Á9%) above the normal range (≤1Á0%). Clinical baseline characteristics were uniformly distributed between patients with normal and elevated HbF levels.
The median number of treatment courses administered was 5 (range 1-23). Fifteen patients had at least two measurements of HbF, of which 13 (81Á3%) showed induction of HbF (to a median of 2Á0%, range 0Á7-4Á0%; Fig 1A) after a median of two courses (range 2-6) of DAC. In the remaining two patients, HbF decreased. Sixteen patients with higher-risk myelodysplastic syndrome (MDS) were treated with low-dose decitabine (DAC, 15 mg/m² over 4 h, administered every 8 h for three consecutive days, repeated every 6 weeks) according to arm A of the 06011 EORTC trial (L€ ubbert et al, 2011) . The number of treatment courses is indicated in column "DAC". Two patients (9, 16) were allowed, after successful application of all 8 treatment courses according to protocol, to cross over to the maintenance phase of the AML 00331 study protocol. HbF baseline values were determined by high performance liquid chromatography directly before start of the first course. Abbreviations: BM, bone marrow; CMMoL, chronic myelomonocytic leukaemia; F, female; HbF, fetal haemoglobin; LDH, lactate dehydrogenase; M, male; n.m., no metaphases obtained; RA, refractory anaemia [French-American-British (FAB) classification; Bennett et al, 1976] ; RAEB, refractory anaemia with blast excess; RAEB-t, refractory anaemia with blast excess in transformation (i.e. acute myeloid leukaemia according to the World Health Organization classification [Swerdlow et al, 2008] Pre-treatment HbF measurements were also collected from 36 AML patients treated on the 00331 trial (Table II) . Median pre-treatment HbF was 0Á65% (range 0Á1-9Á6%). In 12/ 36 patients, HbF levels at baseline were already elevated (median 2Á15%, range 1Á4-9Á6%). A median of two treatment courses were administered (range 1-13). Twenty-four patients had at least two measurements of HbF, of whom 13 (54Á2%) showed induction of HbF to a median of 1Á4% (range 0Á4-13Á3%; Fig 1B) after a median of three courses (range 2-11) of DAC. In the remaining 11 patients, HbF decreased or was not induced to >1%.
These results demonstrate robust in vivo induction of HbF with DAC treatment in MDS and AML patients (while the magnitude of induction is comparable in both diseases, it appears to be more frequent in MDS patients compared to AML). In order to determine whether HbF changes also occur during treatment with other cytidine analogues, such as cytarabine or gemcitabine, HbF levels of four AML patients receiving standard induction chemotherapy (based on 7 days of continuous infusion of cytarabine 100 mg/m²/day)and 4 patients with pancreatic cancer receiving gemcitabine-based treatment (1000 mg/m² gemcitabine on days 1, 8, 15) were also serially measured. None of these patients had HbF induction to >1% (data not shown), underlining the specificity of this effect for a bona fide HMA, such as DAC.
Elevated haemoglobin F levels prior to decitabine treatment are associated with superior outcome of higher-risk MDS patients
We next investigated whether, in the MDS cohort, HbF levels may be prognostic for the outcome to DAC treatment. Thus, we first compared clinical survival endpoints and treatment response of patients with either elevated or normal HbF at baseline. In a second step, we investigated whether HbF induction, over time, in patients with an initially normal HbF would indicate a better outcome than in those where HbF values remained within the normal range during treatment.
The first analysis therefore took the pre-treatment HbF levels of MDS patients into consideration. In the 06011 MDS phase III trial, the primary endpoint was OS. The median OS in patients in the "HbF normal" group (≤1%) was 8Á6 months, compared to 26Á6 months in the "HbF elevated" group (HR = 8Á56, 95% CI 1Á74-42Á49, P = 0Á0083; Fig 2A) . As six patients underwent allogeneic stem cell transplantation (two patients of the "HbF normal" and four patients of the "HbF elevated" group), we censored our observation at time of allografting, with the significantly longer OS being maintained (P = 0Á023, Fig 2B) . The two secondary time-dependent endpoints of the 06011 trial, i.e. PFS and AMLFS, were also interrogated, both showing improved outcome in patients with elevated HbF compared to those with normal HbF levels (Fig 2C, D) . The median PFS in "HbF normal" patients (≤1%) was 5Á9 months, compared to 15Á4 months in group "HbF elevated" (P = 0Á016); AMLFS was 8Á8 months, compared to 26Á3 months (P = 0Á03), respectively.
In the second analysis, we investigated whether elevated HbF, either at baseline or over time, would indicate a better outcome than HbF values remaining within the normal range over time. However, despite the increase in HbF over time in the large majority of patients, this did not improve the prognostic value over the baseline HbF measurements as analysed for OS, PFS and AMLFS by a time-dependent Cox model. Including HbF measurements until Cycle 8 as a time-dependent covariate yielded a HR of 2Á2 (95% CI: 0Á8-6Á6) for OS, a HR of 1Á8 (95% CI: 0Á6-5Á2) for PFS and a HR of 1Á5 (95% CI: 0Á5-4Á2) for AMLFS.
We next looked at the response rates (complete [CR] and partial remission [PR] , haematological improvement [HI]) in both groups, noting a trend towards higher HbF baseline values (median 1Á5%, range 0Á3-3Á9%) in patients achieving a CR, PR or HI compared to non-responders (baseline 0Á4%, range 0Á1-1Á9%, Fig 3) . This difference was not statistically significant.
Elevated haemoglobin F levels prior to decitabine treatment are associated with longer survival of AML patients
We next applied a similar approach, using as an independent cohort the 36 AML patients from the 00331 trial where baseline HbF was available. Patient characteristics by HbF (normal or elevated at baseline) are given in Table II . Here also, OS was longer in the 12 patients with initially elevated HbF compared to the 24 with initially normal HbF: median was 2Á9 months vs. 10Á0 months (HR 3Á01 [95% CI 1Á26-7Á22], P = 0Á014, Fig 4A) . After censoring for allografting (1 patient of the "normal" and 3 patients of the "elevated" HbF group), the OS difference between both patient groups remained borderline significant (P = 0Á053, Fig 4B) . PFS was not determined in this study and therefore could not be interrogated as a second time-dependent endpoint. Regarding response rates (CR, PR, ALE), there were comparable HbF baseline values in the group that did achieve any response vs. the non-responding group (data not shown).
A time-dependent Cox model was generated to interrogate the prognostic impact of HbF increase during the course of therapy on OS. Here also, the model demonstrated inferiority compared to HbF baseline evaluation: for OS, including HbF measurements until Cycle 4 as a time-dependent covariate yielded a HR of 1Á8 (95% CI: 0Á8-3Á9), P = 0Á147.
Finally, we asked whether elevated baseline HbF had independent prognostic value in a multivariate analysis. We consider serum LDH important for a multivariate analysis as one of the key prognostic factors in AML (see for instance Behringer et al, 2003; L€ ubbert et al, 2012) . We therefore performed a multivariate analysis including LDH and age ≥75 years. We entered HbF as an additional factor and compared the models. In this model HbF retained its prognostic value (Table III) .
Discussion
DNA-hypomethylating agents were clinically developed, using low-cytotoxic doses, as inducers of cellular differentiation and (particularly in combination with non-chemotherapy agents, such as retinoids) as biological response modifiers. This concept is based on the gene de-repressive effects observed with the clinically approved agents azacitidine and Thirty-six AML patients with acute myeloid leukaemia (FAB classification; Bennett et al, 1976) were treated with low-dose decitabine (DAC, 15 mg/m² over 3 h, administered every 8 h for three consecutive days, repeated every 6 weeks) according to the AML 00331 study protocol (L€ ubbert et al, 2012 DAC. Specifically, we and others could demonstrate using AML cell line models that in vitro, low-cytotoxic but hypomethylating concentrations of DAC and azacitidine induced marked and distinct transcriptome changes that differed significantly from those mediated by the non-hypomethylating cytidine analogue cytarabine (Flotho et al, 2009; Hollenbach et al, 2010; Qiu et al, 2010) . Despite these unanimous preclinical results, proof for a distinct "clinical fingerprint" of both HMAs compared to cytarabine-based treatment -supporting their alternative mechanism of action in vivo -is as yet limited, even in view of cumulative evidence of their potency to revert DNA hypermethylation of malignant cells in vivo (Treppendahl et al, 2014) . The potential predictive power of induction of a cellular differentiation pathway by HMAs, as was shown descriptively measuring an early platelet response (Van Den Bosch et al, 2004; van der Helm et al, 2011) , has not been widely studied (Treppendahl et al, 2014) . The activation of globin genes by inhibition of DNA methylation achieved by treatment with azanucleoside DNA demethylating agents had already been clinically utilized more than 30 years ago, when low-dose azacitidine treatment of a patient with severe b-thalassaemia resulted in clinically meaningful, prolonged induction of HbF induction (Ley et al, 1982) . This therapeutic principle has since then been confirmed also for sickle-cell anaemia resistant to hydroxycarbamide. Interestingly, however, in vivo HbF induction was also noted in patients with MDS or AML treated with azacitidine in combination with sodium phenylbutyrate (Gore et al, 2006) , and patients treated with DNA demethylating agents for solid tumours (Chu et al, 2013) .
In the present study we investigated whether HbF induction was also observed in vivo (which has not yet been studied systematically with DAC in MDS/AML patients) and whether the HbF level may have prognostic value. HbF was measured by HPLC in 16 MDS patients and 36 AML patients before and, where feasible, after initiation of DAC treatment.
Indeed, we demonstrated induction of HbF by DAC treatment in the majority of the 15 MDS and 24 AML patients, respectively, with serial measurements. This constitutes the first demonstration of recurrent HbF induction in vivo by this hypomethylating agent in MDS/AML patients, and was not observed in patients treated with two other, structurally related cytosine analogues, i.e. cytarabine and gemcitabine (albeit not administered at low-cytotoxic doses).
Analysing the potential clinical value of HbF in this setting, it was notable that HbF levels were already elevated above the upper limit of the normal range before treatment in more than one-third of the patients. Therefore, we first determined clinical outcome, separately in both cohorts, dividing them into those with normal or elevated pre-treatment HbF levels. Strikingly, in both cohorts OS was longer in patients with initially elevated HbF, which in the MDS cohort was also seen for PFS and AMLFS (PFS was not captured in the AML study cohort). Although the initial cohort of the 16 MDS patients did not allow for a uni-and multivariate analysis, this was feasible in the cohort of AML patients, where HbF retained its prognostic value on a scale comparable to serum LDH (one of the most powerful prognostic parameters in AML and MDS). As in regard to the clinical relevance of induction of HbF over time, in timedependent Cox models for both cohorts, patients attaining HbF induction during treatment also had longer survival than those without HbF induction, however the prognostic value was inferior to that of elevated pre-treatment HbF.
Why does DAC-induced HbF elevation correlate with superior outcome to this treatment and, vice versa, why is there an inferior outcome in patients without an HbF response? Reasons for lack of HbF induction achieved could be a mitigated drug effect, e.g. by lower drug plasma levels in the latter patients. But the most striking result, the better survival in patients with elevated pre-treatment HbF, demands a different explanation. It could be speculated that globin genes are already poised for further induction by a low degree or even absence of globin silencing, which may be present also in other genes that become de-repressed before or during a response to hypomethylating treatment. Thus demethylation of a HBB promoter might be a surrogate for demethylation also of other, more disease-relevant genes, such as tumour suppressor genes.
Thus far, there is scarce literature on the role of baseline HbF expression in AML and MDS, particularly as it relates to outcome following specific treatments, with most studies published long before the era of hypomethylating agents. Rautonen and Siimes (1990) described elevated HbF as a poor prognostic factor in 100 children with acute leukaemia. Reinhardt et al (1998) determined pre-therapeutic HbF levels in 26 MDS patients (three of them with refractory anaemia with blast excess in transformation, i.e. AML by the World Health Organization classification; Swerdlow et al, 2008) , and demonstrated elevation in 61Á5%. This was associated with a superior outcome compared to patients with normal HbF. Of note, these patients received variable treatment, ranging from sole best supportive care to standard induction chemotherapy, suggestive of a prognostic, rather than predictive, effect of elevated HbF. Further studies are necessary to determine whether elevated HbF has predictive or prognostic power in MDS/AML. Hypomethylating agents are slow-acting drugs, where the longer-term outcome is often difficult to predict after the first month of treatment, and therefore the clinical need for predictors for outcome is particularly urgent. There are several advantages to pre-treatment HbF (when quantified as described in this study) as a potential biomarker for DAC treatment: it can be measured from peripheral blood (thus no bone marrow aspirate is necessary) and, in contrast to serial measurements, which are heavily dependent on treatment continuation, is informative in all patients. Limitations of our study are the limited number of patients analysed, thus far only at a single centre, and the use of the three-day DAC schedule, which is not frequently used anymore. Regarding the clinical value of baseline HbF, larger studies are therefore warranted in both MDS and AML treated with the established HMA doses and schedules, or with other treatment modalities, such as the EORTC Leukaemia Group trial 1301, where single-agent DAC is compared to standard chemotherapy in AML patients aged 60 years and older ("inDACtion versus induction"). 
